FMP
NeuroSense Therapeutics Ltd.
NRSNW
NASDAQ
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for debilitating neurodegenerative diseases in Israel. Its lead product candidate is PrimeC, a novel oral formulation for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline product candidates include StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
0.46 USD
-0.09 (-19.57%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Mr. Alon Ben-Noon
sector
Healthcare
industry
Biotechnology
exchange
NASDAQ
Description
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for debilitating neurodegenerative diseases in Israel. Its lead product candidate is PrimeC, a novel oral formulation for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline product candidates include StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
CIK
0001875091
ISIN
IL0011811630
CUSIP
M74240116
Address
Medinat ha-Yehudim Street 85
Phone
972 9 953 1142
Country
IL
Employee
18
IPO Date
N/A
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
NRSNW Financial Summary
CIK
0001875091
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
M74240116
ISIN
IL0011811630
Country
IL
Price
0.46
Beta
1.56
Volume Avg.
0
Market Cap
28.91M
Shares
-
52-Week
0.46-0.46
DCF
0.18
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.49
P/B
-
Website
https://www.neurosense-tx.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest NRSNW News
It looks like there's no news available.
